TherapeuticsMD, Inc.(TXMD)Earnings, Financials & Key Ratios
TXMD•NASDAQ
$2.01
$23M mkt cap·Price updated May 7, 2026
AboutTherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Show more
- Revenue$2M+35.3%
- EBITDA-$4M+47.4%
- Net Income-$2M+78.8%
- EPS (Diluted)-0.19+74.3%
- Gross Margin100%
- EBITDA Margin-241.4%+61.1%
- Operating Margin-270.3%+58.7%
- Net Margin-123.85%+84.3%
- ROE-7.7%+75.9%
- ROIC-11.43%+65.3%
- Debt/Equity0.26-4.1%
- Interest Coverage-501.05
TXMD Key Insights
TherapeuticsMD, Inc. (TXMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 93.0%
- ✓FCF machine: 41.6% free cash flow margin
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Sales declining 48.7% over 5 years
- ✗Shares diluted 10.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TXMD Price & Volume
TherapeuticsMD, Inc. (TXMD) stock price & volume — 10-year historical chart
Loading chart...
TXMD Growth Metrics
TherapeuticsMD, Inc. (TXMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-19.3%
5 Years-48.72%
3 Years-11.87%
TTM75.19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM109.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM108%
Return on Capital
10 Years-100.68%
5 Years-106.7%
3 Years-10.71%
Last Year-13.58%
TXMD Peer Comparison
TherapeuticsMD, Inc. (TXMD) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PGNY | 1.57B | 19.16 | 29.48 | 10.4% | 5.23% | 13.34% | 0.05 | |
 DARE | 25.32M | 2.91 | -6.06 | -99.65% | -6.11% | |||
 ANIP | 1.78B | 83.91 | 25.27 | 43.78% | 8.87% | 14.49% | 0.60 | |
 EVAX | 25.71M | 4.07 | -3.36 | 125.81% | -102.38% | -61.62% | 0.44 | |
 ABBV | 358.42B | 202.64 | 85.50 | 8.57% | 6.91% | 62.15% | ||
 PFE | 150.63B | 26.48 | 19.47 | -1.65% | 11.83% | 8.34% | 0.78 | |
 TEVA | 41.93B | 36.01 | 30.01 | 4.31% | 9.02% | 20.69% | 2.20 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 |
Compare TXMD vs Peers
TherapeuticsMD, Inc. (TXMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TXMD Income Statement
TherapeuticsMD, Inc. (TXMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 19.36M | 16.78M | 16.1M | 49.65M | 64.87M | 2.57M | 69.96M | 1.3M | 1.76M | 2.8M |
| Revenue Growth % | -3.9% | -13.32% | -4.04% | 208.38% | 30.67% | -96.03% | 2619.12% | -98.14% | 35.25% | 75.19% |
| Cost of Goods Sold | 4.19M | 2.64M | 2.74M | 6.33M | 15.97M | 1.4M | 1.4M | 0 | 0 | 96K |
| COGS % of Revenue | 21.62% | 15.72% | 17% | 12.76% | 24.63% | 54.49% | 2% | - | - | - |
| Gross Profit | 15.17M▲ 0% | 14.14M▼ 6.8% | 13.36M▼ 5.5% | 43.31M▲ 224.1% | 48.9M▲ 12.9% | 1.17M▼ 97.6% | 68.57M▲ 5755.3% | 1.3M▼ 98.1% | 1.76M▲ 35.3% | 2.7M▲ 0% |
| Gross Margin % | 78.38% | 84.28% | 83% | 87.24% | 75.37% | 45.51% | 98% | 100% | 100% | 96.57% |
| Gross Profit Growth % | -2.98% | -6.79% | -5.51% | 224.15% | 12.89% | -97.61% | 5755.34% | -98.1% | 35.25% | - |
| Operating Expenses | 105.42M | 91.77M | 143.58M | 194.52M | 204.44M | 80.75M | 67.38M | 9.82M | 6.52M | 5.42M |
| OpEx % of Revenue | 544.65% | 546.97% | 891.84% | 391.8% | 315.14% | 3138.28% | 96.3% | 754.61% | 370.3% | - |
| Selling, General & Admin | 51.35M | 57.7M | 115.99M | 174.72M | 194.01M | 72.75M | 56.71M | 0 | 0 | 1.52M |
| SG&A % of Revenue | 265.28% | 343.93% | 720.45% | 351.93% | 299.06% | 2827.36% | 81.06% | - | - | - |
| Research & Development | 53.94M | 33.85M | 27.3M | 19.79M | 10.43M | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | 278.68% | 201.77% | 169.57% | 39.87% | 16.08% | - | - | - | - | - |
| Other Operating Expenses | 367.32K | 695.63K | 0 | 0 | 0 | 8M | 10.66M | 9.82M | 6.52M | 2.99M |
| Operating Income | -90.25M▲ 0% | -77.63M▲ 14.0% | -130.22M▼ 67.7% | -151.21M▼ 16.1% | -155.54M▼ 2.9% | -79.58M▲ 48.8% | 1.19M▲ 101.5% | -8.52M▼ 815.6% | -4.76M▲ 44.2% | -2.71M▲ 0% |
| Operating Margin % | -466.27% | -462.69% | -808.85% | -304.56% | -239.77% | -3092.77% | 1.7% | -654.61% | -270.3% | -97.1% |
| Operating Income Growth % | -5.94% | 13.99% | -67.75% | -16.11% | -2.87% | 48.84% | 101.5% | -815.62% | 44.15% | - |
| EBITDA | -90.12M | -77.42M | -129.93M | -149.81M | -151.47M | -78.84M | 2.39M | -8.08M | -4.25M | -2.33M |
| EBITDA Margin % | -465.59% | -461.42% | -807.02% | -301.76% | -233.5% | -3064.17% | 3.42% | -620.93% | -241.4% | -83.26% |
| EBITDA Growth % | -5.87% | 14.1% | -67.83% | -15.31% | -1.11% | 47.95% | 103.03% | -438.12% | 47.42% | 56.53% |
| D&A (Non-Cash Add-back) | 132.45K | 213.12K | 293.89K | 1.39M | 4.07M | 736K | 1.2M | 438.5K | 509K | 387K |
| EBIT | -89.88M | -76.93M | -127.94M | -159.62M | -157.47M | -71.58M | 10.66M | -8.52M | -3.49M | -1.36M |
| Net Interest Income | 10.82K | 7.7K | -4.68M | -17.38M | -28.58M | -32.92M | 0 | 0 | 135.4K | -7K |
| Interest Income | 10.82K | 7.7K | 0 | - | - | 0 | 0 | 0 | 144.9K | 0 |
| Interest Expense | 0 | 0 | 4.68M | 17.38M | 28.58M | 32.92M | 0 | 0 | 9.5K | 7K |
| Other Income/Expense | 378.14K | 703.33K | -2.4M | -24.94M | -27.98M | 272K | -117K | 781K | 2.42M | 2.73M |
| Pretax Income | -89.88M▲ 0% | -76.93M▲ 14.4% | -132.62M▼ 72.4% | -176.15M▼ 32.8% | -183.52M▼ 4.2% | -79.31M▲ 56.8% | 1.07M▲ 101.4% | -7.74M▼ 820.9% | -2.34M▲ 69.7% | 10K▲ 0% |
| Pretax Margin % | -464.32% | -458.5% | -823.74% | -354.79% | -282.9% | -3082.2% | 1.54% | -594.62% | -133.05% | 0.36% |
| Income Tax | 367.32K | -7.7K | 0 | 0 | 0 | 0 | 0 | -43K | -31K | -63K |
| Effective Tax Rate % | -0.41% | 0.01% | 0% | 0% | 0% | 0% | 0% | 0.56% | 1.32% | -630% |
| Net Income | -89.88M▲ 0% | -76.93M▲ 14.4% | -132.62M▼ 72.4% | -176.15M▼ 32.8% | -183.52M▼ 4.2% | -172.41M▲ 6.1% | 112M▲ 165.0% | -10.28M▼ 109.2% | -2.18M▲ 78.8% | 302K▲ 0% |
| Net Margin % | -464.32% | -458.5% | -823.74% | -354.79% | -282.9% | -6700.93% | 160.08% | -789.4% | -123.85% | 10.8% |
| Net Income Growth % | -5.64% | 14.41% | -72.4% | -32.82% | -4.19% | 6.05% | 164.96% | -109.18% | 78.78% | 109.11% |
| Net Income (Continuing) | -89.88M | -76.93M | -132.62M | -176.15M | -183.52M | -79.31M | 1.07M | -7.7M | -2.31M | 73K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -93.11M | 110.92M | -2.58M | 131K | 229K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -22.92▲ 0% | -18.71▲ 18.4% | -29.47▼ 57.5% | -39.79▼ 35.0% | -38.58▲ 3.0% | -25.83▲ 33.0% | -10.35▲ 59.9% | -0.74▲ 92.9% | -0.19▲ 74.3% | 0.03▲ 0% |
| EPS Growth % | 6.68% | 18.37% | -57.51% | -35.02% | 3.04% | 33.05% | 59.93% | 92.85% | 74.32% | 108% |
| EPS (Basic) | -22.92 | -18.71 | -29.47 | -39.79 | -38.58 | -25.83 | -10.35 | -0.55 | -0.19 | - |
| Diluted Shares Outstanding | 3.92M | 4.11M | 4.5M | 4.93M | 5.51M | 7.96M | 9.03M | 10.44M | 11.53M | 11.57M |
| Basic Shares Outstanding | 3.92M | 4.11M | 4.5M | 4.93M | 5.51M | 7.96M | 9.03M | 10.44M | 11.53M | 11.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TXMD Balance Sheet
TherapeuticsMD, Inc. (TXMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 139.41M | 139.55M | 186.78M | 208.42M | 128.4M | 119.47M | 55.35M | 11.8M | 9.93M | 12.17M |
| Cash & Short-Term Investments | 131.53M | 127.14M | 161.61M | 160.83M | 80.49M | 64.91M | 38.07M | 4.33M | 5.06M | 7.12M |
| Cash Only | 131.53M | 127.14M | 161.61M | 160.83M | 80.49M | 64.91M | 38.07M | 4.33M | 5.06M | 7.12M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 4.5M | 4.33M | 11.06M | 24.4M | 32.38M | 36.18M | 0 | 3.09M | 3.56M | 3.67M |
| Days Sales Outstanding | 84.87 | 94.17 | 250.83 | 179.36 | 182.2 | 5.13K | - | 866.24 | 738.29 | 455.79 |
| Inventory | 1.08M | 1.49M | 3.27M | 11.86M | 7.99M | 7.62M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 93.86 | 205.6 | 435.67 | 683.37 | 182.63 | 1.98K | - | - | - | - |
| Other Current Assets | 0 | 0 | 1.9M | 550.76K | 4.98M | 8.46M | 16.12M | 4.13M | 1.23M | 1.21M |
| Total Non-Current Assets | 3.06M | 3.68M | 25.2M | 57.57M | 53.21M | 50M | 35.11M | 31.51M | 28.9M | 26.5M |
| Property, Plant & Equipment | 516.84K | 437.06K | 472.68K | 12.62M | 11.51M | 9.06M | 7.66M | 6.87M | 6.1M | 5.51M |
| Fixed Asset Turnover | 37.45x | 38.39x | 34.06x | 3.93x | 5.64x | 0.28x | 9.14x | 0.19x | 0.29x | 0.48x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.41M | 3.1M | 24.09M | 44.48M | 41.45M | 7.14M | 6.94M | 6.1M | 4.32M | 3.91M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.01M | 30.28M |
| Other Non-Current Assets | 139.04K | 139.04K | 639.3K | 473.01K | 253K | 33.8M | 20.51M | 18.54M | 2.46M | 36.17M |
| Total Assets | 142.47M▲ 0% | 143.23M▲ 0.5% | 211.98M▲ 48.0% | 265.99M▲ 25.5% | 181.61M▼ 31.7% | 169.47M▼ 6.7% | 90.46M▼ 46.6% | 43.31M▼ 52.1% | 38.82M▼ 10.4% | 38.67M▲ 0% |
| Asset Turnover | 0.14x | 0.12x | 0.08x | 0.19x | 0.36x | 0.02x | 0.77x | 0.03x | 0.05x | 0.07x |
| Asset Growth % | 93.24% | 0.53% | 48% | 25.47% | -31.72% | -6.68% | -46.62% | -52.12% | -10.36% | -25.78% |
| Total Current Liabilities | 14.98M | 13.32M | 41.08M | 53M | 59.24M | 252.89M | 46.84M | 6.85M | 5.17M | 4.95M |
| Accounts Payable | 7.36M | 4.1M | 22.74M | 19.18M | 21.07M | 3.37M | 2.16M | 27K | 258K | 263K |
| Days Payables Outstanding | 641.67 | 567.18 | 3.03K | 1.11K | 481.37 | 878.13 | 564.87 | - | - | 995.2 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 188.27M | 0 | 0 | 1.63M | 1.07M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 14.13M | 7.06M | 47.91M | 30.53M | 3.69M | 3.16M | 3.35M |
| Current Ratio | 9.30x | 10.48x | 4.55x | 3.93x | 2.17x | 0.47x | 1.18x | 1.72x | 1.92x | 1.92x |
| Quick Ratio | 9.23x | 10.36x | 4.47x | 3.71x | 2.03x | 0.44x | 1.18x | 1.72x | 1.92x | 1.92x |
| Cash Conversion Cycle | -462.95 | -267.41 | -2.35K | -242.42 | -116.54 | 6.24K | - | - | - | -539.4 |
| Total Non-Current Liabilities | 0 | 0 | 73.38M | 203.78M | 246.37M | 10.2M | 8.48M | 7.17M | 6.29M | 6.28M |
| Long-Term Debt | 0 | 0 | 73.38M | 194.63M | 237.7M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 9.15M | 8.68M | 8.06M | 7.37M | 6.53M | 5.54M | 22.63M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 2.14M | 1.11M | 636K | 744K | 3.24M |
| Total Liabilities | 14.98M | 13.32M | 114.46M | 256.78M | 305.61M | 263.09M | 55.31M | 14.02M | 11.45M | 11.23M |
| Total Debt | 0 | 0 | 73.38M | 205.28M | 248.63M | 197.69M | 8.76M | 8.01M | 7.17M | 6.48M |
| Net Debt | -131.53M | -127.14M | -88.23M | 44.45M | 168.14M | 132.79M | -29.31M | 3.68M | 2.12M | -632K |
| Debt / Equity | - | - | 0.75x | 22.31x | - | - | 0.25x | 0.27x | 0.26x | 0.26x |
| Debt / EBITDA | - | - | - | - | - | - | 3.66x | - | - | -2.78x |
| Net Debt / EBITDA | - | - | - | - | - | - | -12.26x | - | - | 0.27x |
| Interest Coverage | - | - | -27.84x | -8.70x | -5.44x | -2.42x | - | - | -501.05x | -194.43x |
| Total Equity | 127.49M▲ 0% | 129.91M▲ 1.9% | 97.52M▼ 24.9% | 9.2M▼ 90.6% | -124M▼ 1447.7% | -93.62M▲ 24.5% | 35.14M▲ 137.5% | 29.29M▼ 16.7% | 27.37M▼ 6.5% | 27.44M▲ 0% |
| Equity Growth % | 102.16% | 1.9% | -24.93% | -90.57% | -1447.67% | 24.5% | 137.54% | -16.66% | -6.55% | -13.33% |
| Book Value per Share | 32.51 | 31.60 | 21.67 | 1.87 | -22.49 | -11.76 | 3.89 | 2.81 | 2.37 | 2.37 |
| Total Shareholders' Equity | 127.49M | 129.91M | 97.52M | 9.2M | -124M | -93.62M | 35.14M | 29.29M | 27.37M | 27.44M |
| Common Stock | 196.69K | 216.43K | 240.46K | 271.18K | 300K | 9K | 9K | 11K | 11K | 11K |
| Retained Earnings | -309.7M | -386.66M | -519.28M | -695.42M | -878.95M | -1.05B | -939.36M | -949.64M | -951.82M | -951.77M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -230.62K | -372.22K | -553.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TXMD Cash Flow Statement
TherapeuticsMD, Inc. (TXMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -69.14M | -76.16M | -106.81M | -165.7M | -159.47M | -147.81M | -4.08M | -48.14M | 732K | 732K |
| Operating CF Margin % | -357.21% | -453.91% | -663.45% | -333.75% | -245.82% | -5744.69% | -5.83% | -3697.47% | 41.57% | - |
| Operating CF Growth % | 12.53% | -10.14% | -40.25% | -55.13% | 3.76% | 7.31% | 97.24% | -1080.51% | 101.52% | 6838.16% |
| Net Income | -89.88M | -76.93M | -132.62M | -176.15M | -183.52M | -79.31M | 1.07M | -7.7M | -2.31M | 302K |
| Depreciation & Amortization | 132.45K | 213.12K | 293.89K | 1.39M | 4.07M | 736K | 1.19M | 922K | 509K | 387K |
| Stock-Based Compensation | 17.41M | 6.89M | 8.66M | 10.68M | 10.68M | 0 | 11.57M | 0 | 0 | 24K |
| Deferred Taxes | 0 | 0 | 216.02K | 10.44M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.52M | 4.21K | 269.86K | 1.92M | 12.65M | -73.83M | -13.83M | -23.92M | 875K | -196K |
| Working Capital Changes | 664.75K | -6.34M | 16.36M | -14M | -3.34M | 4.59M | -4.09M | -17.45M | 1.66M | 1.64M |
| Change in Receivables | -3.98M | 167.69K | -6.95M | -13.64M | -8.22M | -4.33M | 0 | 0 | 0 | 0 |
| Change in Inventory | -386.17K | -409.04K | -1.78M | -8.59M | -3.34M | -711K | 0 | 0 | 0 | 0 |
| Change in Payables | 4.23M | -3.26M | 18.65M | -3.56M | 1.89M | -1.06M | -1.21M | -2.13M | 231K | 5K |
| Cash from Investing | -1.26M | -827.11K | -21.5M | -23.91M | -1.6M | -2.22M | 223.48M | 0 | 0 | 0 |
| Capital Expenditures | -1.24M | -827.11K | -21.32M | -23.89M | -207K | -2.22M | -355K | 0 | 0 | 0 |
| CapEx % of Revenue | 6.41% | 4.93% | 132.44% | 48.12% | 0.32% | 86.4% | 0.51% | 3697.47% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -14.04K | -765.29K | -175.41K | -20.42K | -1.39M | 0 | 223.83M | 0 | 0 | 0 |
| Cash from Financing | 137.23M | 72.58M | 162.79M | 188.83M | 80.72M | 134.67M | -235.21M | 3.15M | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 75M | 118.34M | 50M | -50M | -219.43M | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -38.66M | 0 | 0 | 0 |
| Other Financing | 2.36M | 4.01M | -2.12M | -6.54M | -978K | 0 | -1.27M | 0 | 0 | 0 |
| Net Change in Cash | 66.83M▲ 0% | -4.4M▼ 106.6% | 34.48M▲ 883.9% | -783.36K▼ 102.3% | -80.34M▼ 10156.3% | -15.58M▲ 80.6% | -15.8M▼ 1.5% | -44.99M▼ 184.7% | 732K▲ 101.6% | 2.07M▲ 0% |
| Free Cash Flow | -70.38M▲ 0% | -76.98M▼ 9.4% | -128.13M▼ 66.4% | -189.59M▼ 48.0% | -161.07M▲ 15.0% | -147.84M▲ 8.2% | -4.43M▲ 97.0% | 0▲ 100.0% | 732K▲ 0% | 2.07M▲ 0% |
| FCF Margin % | -363.62% | -458.84% | -795.89% | -381.88% | -248.29% | -5746.02% | -6.34% | - | 41.57% | 73.96% |
| FCF Growth % | 11.61% | -9.38% | -66.45% | -47.96% | 15.04% | 8.21% | 97% | 100% | - | 187.22% |
| FCF per Share | -17.95 | -18.73 | -28.47 | -38.48 | -29.22 | -18.57 | -0.49 | - | 0.06 | 0.06 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.99x | 0.81x | 0.94x | 0.87x | 0.86x | -0.04x | 4.68x | -0.34x | 6.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 25.85M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TXMD Key Ratios
TherapeuticsMD, Inc. (TXMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -94.33% | -59.77% | -116.62% | -330.09% | - | - | 318.69% | -31.9% | -7.7% | 1.1% |
| Return on Invested Capital (ROIC) | - | -2099.52% | -1618.96% | -360.33% | -238.58% | -143.29% | 3.97% | -32.95% | -11.43% | -11.43% |
| Gross Margin | 78.38% | 84.28% | 83% | 87.24% | 75.37% | 45.51% | 98% | 100% | 100% | 96.57% |
| Net Margin | -464.32% | -458.5% | -823.74% | -354.79% | -282.9% | -6700.93% | 160.08% | -789.4% | -123.85% | 10.8% |
| Debt / Equity | - | - | 0.75x | 22.31x | - | - | 0.25x | 0.27x | 0.26x | 0.26x |
| Interest Coverage | - | - | -27.84x | -8.70x | -5.44x | -2.42x | - | - | -501.05x | -194.43x |
| FCF Conversion | 0.77x | 0.99x | 0.81x | 0.94x | 0.87x | 0.86x | -0.04x | 4.68x | -0.34x | 6.85x |
| Revenue Growth | -3.9% | -13.32% | -4.04% | 208.38% | 30.67% | -96.03% | 2619.12% | -98.14% | 35.25% | 75.19% |
TXMD Frequently Asked Questions
TherapeuticsMD, Inc. (TXMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TherapeuticsMD, Inc. (TXMD) reported $2.8M in revenue for fiscal year 2024. This represents a 1328% increase from $0.2M in 1995.
TherapeuticsMD, Inc. (TXMD) grew revenue by 35.3% over the past year. This is strong growth.
Yes, TherapeuticsMD, Inc. (TXMD) is profitable, generating $0.3M in net income for fiscal year 2024 (-123.9% net margin).
Dividend & Returns
TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -7.7%. Negative ROE indicates the company is unprofitable.
TherapeuticsMD, Inc. (TXMD) generated $2.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TXMD
TherapeuticsMD, Inc. (TXMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates